Home >> Research Area >> Broxyquinoline

Broxyquinoline

CAS# 521-74-4

Broxyquinoline

Catalog No. BCC4642----Order now to get a substantial discount!

Product Name & Size Price Stock
Broxyquinoline: 5mg $12 In Stock
Broxyquinoline: 10mg Please Inquire In Stock
Broxyquinoline: 20mg Please Inquire Please Inquire
Broxyquinoline: 50mg Please Inquire Please Inquire
Broxyquinoline: 100mg Please Inquire Please Inquire
Broxyquinoline: 200mg Please Inquire Please Inquire
Broxyquinoline: 500mg Please Inquire Please Inquire
Broxyquinoline: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Broxyquinoline

Number of papers citing our products

Chemical structure

Broxyquinoline

3D structure

Chemical Properties of Broxyquinoline

Cas No. 521-74-4 SDF Download SDF
PubChem ID 2453 Appearance Powder
Formula C9H5Br2NO M.Wt 302.95
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 33.33 mg/mL (110.02 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name 5,7-dibromoquinolin-8-ol
SMILES C1=CC2=C(C(=C(C=C2Br)Br)O)N=C1
Standard InChIKey ZDASUJMDVPTNTF-UHFFFAOYSA-N
Standard InChI InChI=1S/C9H5Br2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Broxyquinoline Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Broxyquinoline Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Broxyquinoline

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.3009 mL 16.5044 mL 33.0087 mL 66.0175 mL 82.5219 mL
5 mM 0.6602 mL 3.3009 mL 6.6017 mL 13.2035 mL 16.5044 mL
10 mM 0.3301 mL 1.6504 mL 3.3009 mL 6.6017 mL 8.2522 mL
50 mM 0.066 mL 0.3301 mL 0.6602 mL 1.3203 mL 1.6504 mL
100 mM 0.033 mL 0.165 mL 0.3301 mL 0.6602 mL 0.8252 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Broxyquinoline

Broxyquinoline is an antiprotozoal agent and able to release oxygen free radicals from the water in mucous membranes.

Featured Products
New Products
 

References on Broxyquinoline

A study on the neurotoxicity of broxyquinoline and brobenzoxaldine combination in therapeutic doses.[Pubmed:3081428]

Hum Toxicol. 1986 Jan;5(1):35-41.

The neurotoxicity of a combination of Broxyquinoline and brobenzoxaldine (Intestopan Forte, containing 500 mg and 100 mg of the drugs respectively per capsule) was investigated by prospective clinical and electrophysiological studies in patients and volunteer subjects given the drugs in therapeutic doses (two capsules three times a day for 5 days). Of 16 patients with intestinal amoebiasis given the drugs (study A), 13 (81.25%) were cured. Adverse effects were mild and did not affect treatment. No neurological adverse effect was reported. Neurological examinations revealed no abnormality in any patient after treatment. Seven volunteer subjects underwent medical, neurological and ophthalmological examinations, and electrophysiological studies of ulnar and peroneal nerve conduction before and after treatment with the drugs in therapeutic doses (study B). Transient paresthesias were reported by one subject on the fourth day of treatment. No medical, neurological or ophthalmological abnormality was detected in any subject after treatment. There was no significant change in motor nerve conduction velocities. There was a significant (P less than 0.001) increase in the stimulus strength for distal ulnar stimulation and a significant (P less than 0.01) decrease in stimulus duration for proximal and distal ulnar stimulation. No significant changes were seen in the peroneal nerves in these parameters. No qualitative abnormality was seen in the oscilloscopic patterns of nerve conduction after treatment. Literature on the neurotoxicity of the halogenated hydroxyquinolines is reviewed. It is concluded that Broxyquinoline and brobenzoxaldine (and probably other halogenated hydroxyquinolines as well) are safe and effective in therapeutic doses; neurotoxicity is unlikely to occur when these drugs are used according to therapeutic recommendations.

Impairment of exercise tolerance due to broxyquinoline-brobenzoxaldine combination.[Pubmed:3081430]

Hum Toxicol. 1986 Jan;5(1):63-4.

A case report of impaired exercise tolerance during administration of Broxyquinoline-brobenzoxaldine combination in therapeutic doses is presented. The first author of this paper, a 28-year-old healthy male, volunteered as a subject for a prospective study on the neurotoxicity of halogenated hydroxyquinolines and took a course of Broxyquinoline-brobenzoxaldine combination. The author, who is a karate enthusiast, observed impairment of exercise tolerance during the course of treatment with the drugs. A challenge course of treatment with the same drugs in the same doses produced similar effects. Since halogenated hydroxyquinolines are still used widely in many countries, such an adverse effect would be of practical relevance, particularly in asymptomatic cyst-passers of Entamoeba histolytica whose occupations involve physical labour.

Description

Broxyquinoline is an antiprotozoal agent.

Keywords:

Broxyquinoline,521-74-4,Natural Products, buy Broxyquinoline , Broxyquinoline supplier , purchase Broxyquinoline , Broxyquinoline cost , Broxyquinoline manufacturer , order Broxyquinoline , high purity Broxyquinoline

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: